Sugi Predict

Sugi Predict / Compounds / SCHEMBL597104

SCHEMBL597104

SCHEMBL597104

c1ccc2c(c1)ccc1c(-c3ncc[nH]3)cccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 3/20 0.50
▸ ADRA2B P18089 2/20 0.50
▸ ADRA2C P18825 2/20 0.50
▸ CSNK1A1 P48729 1/20 0.50
▸ TYRO3 Q06418 1/20 0.50
▸ DYRK1B Q9Y463 1/20 0.50
▸ HPRT1 P00492 2/20 0.47
▸ NISCH Q9Y2I1 2/20 0.46
▸ MTOR P42345 1/20 0.46
▸ ADK P55263 1/20 0.46
▸ IDO1 P14902 1/20 0.46
▸ LMNA P02545 3/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ APEX1 P27695 1/20 0.45
▸ PMP22 Q01453 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51007 0.91 ADRA2A (0.54) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
Hydrochloric Acid SCHEMBL28957351 0.90 ADRA2A (0.56) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL26259965 0.86 NISCH (0.54) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL26259955 0.84 NISCH (0.61) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL21298118 0.83 ADRA2A (0.49) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL14886220 0.83 CSNK1A1 (0.53) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL31429565 0.80 ADRA2A (0.50) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL8118221 0.80 ADRA2A (0.50) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL4721867 0.80 ADRA2A (0.46) ADRA2AADRA2BADRA2CCSNK1A1TYRO3
SCHEMBL27843956 0.79 NISCH (0.53) ADRA2AADRA2BADRA2CCSNK1A1TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572284-A Crosslinkable host material 三星显示有限公司 2023-01-06 — — CN claimed
US-20180358414-A1 ORGANIC ELECTROLUMINESCENT DEVICE KUNSHAN NEW FLAT PANEL DISPLAY TECHNOLOGY CENTER CO., LTD. (CN) 2018-12-13 — — US claimed
US-20180334473-A1 Arene Ruthenium Complex, Preparation Method and Utilization Thereof GUANGDONG PHARMACEUTICAL UNIVERSITY (CN) 2018-11-22 — — US claimed
EP-3364459-A1 ORGANIC ELECTROLUMINESCENT DEVICE Kunshan New Flat Panel Display Technology Center Co., Ltd. (CN) 2018-08-22 — — EP claimed
WO-2024112287-A1 BENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BANOGLU ERDEN (TR) 2024-05-30 — — WO disclosed
WO-2023093094-A1 ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY APPARATUS 昆山国显光电有限公司 2023-06-01 — — WO disclosed
WO-2023284022-A1 PHENANTHROIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 广东工业大学 2023-01-19 — — WO disclosed
CN-115572284-A Crosslinkable host material 三星显示有限公司 2023-01-06 — — CN disclosed
CN-108884390-B Intermediates and procedures for the synthesis of functional materials 默克专利股份有限公司 2022-05-31 — — CN disclosed
CN-114514627-A Organic electroluminescent green light emitting device 赛诺拉有限公司 2022-05-17 — — CN disclosed
US-11322690-B2 Light harvesting array FLUROSOL INDUSTRIES PTY LTD (AU) 2022-05-03 — — US disclosed
CN-113659086-A White light organic electroluminescent device with low efficiency roll-off and high spectral stability and preparation method thereof 盐城吉研智能科技有限公司 2021-11-16 — — CN disclosed
US-20080015335-A1 Soluble phenanthrenyl imidazole for photo-electrical conversion of solar cell NATIONAL CHIAO TUNG UNIVERSITY (TW) 2008-01-17 — — US disclosed
WO-2007124589-A1 METHODS FOR TREATING OR PREVENTING NEOPLASIAS MERCK FROSST CANADA LTD. (CA) 2007-11-08 — — WO disclosed
US-20070208017-A1 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors MERCK CANADA INC. (CA) 2007-09-06 — — US disclosed
EP-1828143-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS Merck Frosst Canada Ltd. (CA) 2007-09-05 — — EP disclosed
WO-2007095753-A1 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES MERCK FROSST CANADA LTD. (CA) 2007-08-30 — — WO disclosed
WO-2007059610-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 — — WO disclosed
WO-2007059611-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 — — WO disclosed
WO-2006063466-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208017-A1 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors PTGS1, PTGES, PTGES2 ADRA2A 715/4885ADRA2B 1015/4885ADRA2C 580/4885
US-20180334473-A1 Arene Ruthenium Complex, Preparation Method and Utilization Thereof CBR3, CBR1, C1R ADRA2A 1772/4885ADRA2B 1171/4885ADRA2C 905/4885
US-11322690-B2 Light harvesting array SUN2, ALG8, GNE ADRA2A 4350/4885ADRA2B 4744/4885ADRA2C 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.